Subsequently, we used the model to test different treatment scenarios and identify optimum treatment strategies for the combination of vasculature and stroma normalizing agents and CAR-T cells or anti-VEGF producing CAR-T cells, or anti-VEGF producing FAP-CAR-T cell therapies for GBM and other solid tumors. The gene discussed is FAP; the disease is glioblastoma.